Polymorphisms in interstitial lung diseases: Friend or foe?

dr. P.A.H.M. Wijnen

Chapter 01 – General introduction

Chapter 02 – Relationship between drug-induced interstitial lung diseases and CYP polymorphisms

Chapter 03 – Pharmacogenetic testing after a simple DNA isolation method

Chapter 04 – Role of cytochrome P450 polymorphisms in the development A of pulmonary drug toxicity. case-control study in the Netherlands

Chapter 05 – Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity

Chapter 06 – Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar haemorrhage caused by oral anticoagulants 

Chapter 07 – The role of TNF-a G-308A polymorphisms in the course of pulmonary sarcoidosis

Chapter 08 – Butyrophilin-like 2 in pulmonary sarcoidosis: a factor for susceptibility and progression?

Chapter 09 – Summary, general discussion and directions for future research

Chapter 10 – Samenvatting

Chapter 11 – Appendix

Chapter 12 – List of publications

Chapter 13 – Dankwoord

Chapter 14 – Curriculum vitae

Terug